Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Repare Therapeutics is a clinical-stage biotech specializing in precision oncology through synthetic lethality. Using its proprietary SNIPRx platform, it develops targeted small-molecule therapeutics for genetically-defined cancers, focusing on DNA repair and genomic instability. Its portfolio includes candidates like RP-3467 and RP-1664, targeting DNA polymerase theta and PLK4, respectively. The company collaborates with industry partners, relies on third-party manufacturing, and aims to advance cancer treatments with a competitive edge in targeted therapy development.
This description was generated via AI from an annual report. Updated about 1 year ago.